Evidence map›Paper›PMID 21998743›Full record

ArticlePloS one2011

A system for performing high throughput assays of synaptic function.

Chris M Hempel, Michael Sivula, Jonathan M Levenson, David M Rose, Bing Li, Ana C Sirianni, Eva Xia, Timothy A Ryan, David J Gerber, Jeffrey R Cottrell

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2013
    Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Chris M HempelGalenea Corporation, Cambridge, Massachusetts, United States of America.
Michael Sivula
Jonathan M Levenson
David M Rose
Bing Li
Ana C Sirianni
Eva Xia
Timothy A Ryan
David J Gerber
Jeffrey R Cottrell
Galenea (United States) · USGalena Biopharma (United States) · USCornell University · US

Funding

Mechanism-based, pro-cognitive therapies for schizophreniaRC4MH092889 · NIMH · GALENEA CORPORATION · PI GERBER, DAVID JULIAN · 2010 to 2010
$4.5M
Quantitative Mapping of Molecules and Release Properties at Nerve TerminalsR01MH085783 · NIMH · WEILL MEDICAL COLL OF CORNELL UNIV · PI RYAN, TIMOTHY AIDAN · 2010 to 2019
$4.4M
NIMH NIH HHS 1RC4MH092889-01NIMH NIH HHS R01 MH085783NIMH NIH HHS RC4 MH092889
6 · The paper itself

Abstract

Unbiased, high-throughput screening has proven invaluable for dissecting complex biological processes. Application of this general approach to synaptic function would have a major impact on neuroscience research and drug discovery. However, existing techniques for studying synaptic physiology are labor intensive and low-throughput. Here, we describe a new high-throughput technology for performing assays of synaptic function in primary neurons cultured in microtiter plates. We show that this system can perform 96 synaptic vesicle cycling assays in parallel with high sensitivity, precision, uniformity, and reproducibility and can detect modulators of presynaptic function. By screening libraries of pharmacologically defined compounds on rat forebrain cultures, we have used this system to identify novel effects of compounds on specific aspects of presynaptic function. As a system for unbiased compound as well as genomic screening, this technology has significant applications for basic neuroscience research and for the discovery of novel, mechanism-based treatments for central nervous system disorders.

Indexed as

AnimalsCells, CulturedDrug DiscoveryHigh-Throughput Screening AssaysNeuronsRatsSynapsesSynaptic VesiclesTime Factors

Identifiers

PMID21998743
PMCPMC3187845
OpenAlexW2054602685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.